AMLX
AMLX clinical trials: Amylyx Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Amylyx Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 13
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
AMLX on the catalyst calendar · AMLX registry changes
- Primary completion Not registeredNo phase registeredNCT07582874An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric HypoglycemiaAmylyx Pharmaceuticals Inc. · Post-bariatric HypoglycemiaAvailableAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05286372An Intermediate Size Expanded Access Protocol of AMX0035 for ALSAmylyx Pharmaceuticals Inc. · Amyotrophic Lateral SclerosisNo longer availableAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 8, 2026ActualPhase 3NCT06747468Avexitide for Treatment of Post-Bariatric HypoglycemiaAmylyx Pharmaceuticals Inc. · Post Bariatric HypoglycemiaActive, not recruitingAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2025ActualPhase 2/Phase 3NCT06122662AMX0035 and Progressive Supranuclear PalsyAmylyx Pharmaceuticals Inc. · Progressive Supranuclear PalsyCompletedAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2027Sponsor estimatePhase 1NCT06665165AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisAmylyx Pharmaceuticals Inc. · ALSRecruitingAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2024ActualPhase 2NCT05676034AMX0035 in Adult Patients With Wolfram SyndromeAmylyx Pharmaceuticals Inc. · Wolfram SyndromeActive, not recruitingAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2021ActualPhase 2NCT03488524Open Label Extension Study of AMX0035 in Patients With ALSAmylyx Pharmaceuticals Inc. · Amyotrophic Lateral SclerosisCompletedAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 22, 2020ActualPhase 2NCT03533257Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's DiseaseAmylyx Pharmaceuticals Inc. · Alzheimer DiseaseCompletedAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 16, 2024ActualPhase 3NCT05619783Extension Study Evaluating The Safety And Tolerability of AMX0035Amylyx Pharmaceuticals Inc. · Amyotrophic Lateral SclerosisCompletedAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2024ActualPhase 3NCT05021536Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentAmylyx Pharmaceuticals Inc. · Amyotrophic Lateral SclerosisUnknown statusAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 25, 2019ActualPhase 2NCT03127514AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)Amylyx Pharmaceuticals Inc. · Amyotrophic Lateral SclerosisCompletedAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2022ActualPhase 1/Phase 2NCT04987671Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALSAmylyx Pharmaceuticals Inc. · ALSUnknown statusAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2022ActualPhase 2/Phase 3NCT04516096A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)Amylyx Pharmaceuticals Inc. · Amyotrophic Lateral SclerosisCompletedAMLXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner